GT Medical Acquires Radioactive Seed Assets From Perspective Therapeutics

GT Medical Technologies, Inc. announced it has agreed to acquire substantially all of the radioactive Cesium-131 seed assets and related business infrastructure from Isoray Medical, which is a subsidiary of Perspective Therapeutics, Inc. (“Isoray”). GT Medical Technologies’ GammaTile Therapy is FDA-cleared to treat patients with operable brain tumors to eliminate residual tumor cells. Full market release for this technology occurred in March 2020, and over 100 leading brain tumor treatment centers have adopted GammaTile to date. The transaction is expected to decrease the required lead times from the customer order to product delivery, allowing even more patients to benefit from this technology. The closing of the transaction is subject to satisfaction of customary conditions to closing and is expected to close in the first quarter of 2024.

The acquisition would strengthen GT Medical Technologies’ position in the market by ensuring access to and control of radioactive seed production. The seeds are a key component of GammaTile Therapy for patients undergoing brain tumor resection surgeries with the need for adjuvant radiation therapy. In addition, the acquisition has the potential to expand GT Medical Technologies’ customer base to include multiple facilities treating patients with prostate, lung, head & neck, and gynecological tumors.

“By agreeing to acquire Cesium-131-related assets from Isoray, GT Medical Technologies is poised to enhance the delivery of GammaTile Therapy in the US market, building on our commitment to excellence for both patients and the clinicians who treat them,” said GT Medical Technologies CEO Matthew Likens. “Also, acquiring the legacy Isoray business will allow us to streamline existing operations and deepen our partnership with the radiation oncologist community. We are excited about integrating with Isoray’s Cesium-131 brachytherapy team following the closing of the transaction.”

“We think GT Medical Technologies believes in the future of brachytherapy and have been a major innovator and investor in the technology in recent years,” said Perspective Therapeutics CEO Thijs Spoor. “The transaction is expected to create a dominant force in US and global brachytherapy, focusing on, and investing in improved outcomes for patients with multiple tumors using a single best in class isotope. This will allow Perspective Therapeutics to increase focus on accelerating clinical development of our proprietary alpha-particle therapy portfolio, with the added confidence that Cesium-131 as a brachytherapy technology, and the incredibly talented team dedicated to its production and commercialization, is in excellent hands.”

GammaTile consists of bioresorbable collagen embedded with Cesium-131 radioactive seeds. This Surgically Targeted Radiation Therapy (STaRT) starts radiation immediately after tumor removal to help eradicate residual tumor cells.